<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01920802</url>
  </required_header>
  <id_info>
    <org_study_id>6525</org_study_id>
    <nct_id>NCT01920802</nct_id>
  </id_info>
  <brief_title>Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo</brief_title>
  <official_title>Quantitative Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking the Antipsychotic Medications Fanapt (Iloperidone) or Zyprexa (Olanzapine) or Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot randomized clinical trial is to begin to delineate the
      pathophysiological changes associated with antipsychotic associated metabolic side effects.
      The study will be performed in 36 healthy people between the ages of 18 and 30, who have
      never taken an antipsychotic, will undergo baseline laboratory tests before being randomized
      to 5mg BID of olanzapine or 6mg BID of iloperidone or placebo to take for up to 4 weeks. The
      primary outcome measure will be a correlation of early changes in leptin with weight gain. We
      will also record changes in food intake, resting metabolic rate, oral glucose tolerance and
      fasting insulin and glucose levels, lipids and inflammation markers. Subjects will be
      followed closely to monitor for safety throughout the 4-week study and will be discontinued
      if there is a medically significant change in metabolic status or other antipsychotic side
      effects. Metabolic assessments will be performed again at the time of discontinuation or at
      the end of an 4-week period, and change from baseline in the two treatment groups will be
      compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study hypotheses:

        1. Early changes (baseline vs day 3) in leptin will correlate with later changes in weight
           (at study termination.)

             1. Olanzapine will cause the greatest increase in calorie consumption from baseline on
                the multi-item meal compared with iloperidone or placebo.

             2. Olanzapine subjects will report the greatest frequency/quantity of eating in food
                diaries, and report increased preference for calorically dense foods (ie, higher
                fat content) compared to iloperidone or placebo.

             3. Early markers of endocrine changes caused by olanzapine will be greater than those
                caused by iloperidone or placebo, and these early changes will correlate with
                weight gain.

        2. Olanzapine will have greater effects on glucose homeostasis than iloperidone or placebo,
           and these effects will be separate from effects on body weight and composition.

             1. Early signs of metabolic disturbance, including glucose intolerance (greater
                excursion on OGTT) and insulin resistance (higher plasma insulin) will precede any
                significant weight gain.

             2. Early evidence of glucose intolerance and/or insulin resistance will predict
                greater metabolic derangements with further dosing of olanzapine, as evidenced by
                exacerbated glucose intolerance on OGTT or higher plasma glucose/insulin levels.
                These effects may not necessarily parallel weight gain.

             3. Olanzapine will be associated with greater markers of inflammation than iloperidone
                or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>baseline and 6 week visit</time_frame>
    <description>Delineate a pathophysiological mechanism of antipsychotic induced weight gain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Adiposity</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Total fat mass (excluding head) from baseline to Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Leptin</measure>
    <time_frame>change in baseline to Day 3</time_frame>
    <description>Leptin levels measured at Day 3 compared to baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change Glucose in People Taking Olanzapine or Iloperidone</measure>
    <time_frame>Baseline to study termination (about 12 weeks)</time_frame>
    <description>To quantify, prospectively, change in glucose from baseline to Day 28</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Insulin</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Change in Insulin levels from baseline to Day 28</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin Resistance</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Homeostatic model assessment for Insulin Resistance (HOMA-IR) is a method for assessing Î²-cell function and insulin resistance (IR) from basal (fasting) glucose and insulin.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Food Intake</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Total grams of food consumed</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Lipid Metabolism</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Change in lipid metabolism as measured by cholesterol/HDL ratio</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg BID olanzapine for up to 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iloperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6mg BID iloperidone up to 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BID placebo up to 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>5mg BID up to 4 weeks</description>
    <arm_group_label>olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iloperidone</intervention_name>
    <description>6 mg BID up to 4 weeks</description>
    <arm_group_label>iloperidone</arm_group_label>
    <other_name>Fanapt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>BID up to 4 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between the ages of 18-35 with no history of any Axis-I diagnosis

          -  Does not meet criteria for substance abuse or dependence in the past six months

          -  Female subjects will use barrier-method, non-hormonal contraception

          -  Capacity to understand all the relevant risks and potential benefits of the study
             (informed consent)

          -  Must be able to speak and read English

        Exclusion Criteria:

          -  Current or past Axis I psychiatric diagnosis, including alcohol or substance abuse or
             dependence (except nicotine or caffeine), but not including minor Axis I disorders
             (e.g. simple phobia)

          -  Lifetime use of psychotropic medications, including antipsychotics, antidepressants,
             mood stabilizers, and anxiolytics

          -  Presence or history of medical or neurological illness that, in the judgment of the
             investigator, could influence the results of the study

          -  Diagnosis of diabetes, hemoglobin A1C &gt; 6.5, hypertension, or dyslipidemias, or
             elevated random or fasting glucose, abnormal lipid levels, BP 130/85

          -  BMI 25 or &lt; 19, history of BMI &gt;35, and/or waist circumference &gt;35 inches for females,
             40 inches for males

          -  Subjects who are pregnant or breast-feeding or planning to become pregnant during the
             study

          -  Acute suicidality

          -  Meets criteria for a Diagnostic and Statistical Manual, Version 4 (DSM-IV) defined
             eating disorder

          -  Use of, or clinical indication for, one or more of the following medications: lithium,
             anti-epileptic medication, steroids (oral or inhaled), stimulants, serotonin reuptake
             inhibitors, mirtazapine, tricyclic antidepressants, thyroid supplementation,
             sibutramine, metformin, thiazolidinediones, beta-blockers, clonidine, niacin

          -  Subjects who have had &gt;10% change in their body weight within the three months prior
             to enrollment

          -  HIV positive subjects

          -  Presence of mental retardation or pervasive developmental disorder

          -  History of recent (within 6 months) significant self-injurious behavior or violence

          -  Daily multivitamin or B-complex vitamin use

          -  A known history of dieting and difficulty with weight loss

          -  A strong family history of diabetes and/or heart disease

          -  History of congenital long QT syndrome or prolonged corrected QT interval (QTc) on
             screening EKG (&gt;450ms)

          -  Concomitant use of any medication that inhibits 2D6 or 3A4 metabolism

          -  Low serum potassium or magnesium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Lieberman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2013</study_first_submitted>
  <study_first_submitted_qc>August 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2013</study_first_posted>
  <results_first_submitted>September 22, 2016</results_first_submitted>
  <results_first_submitted_qc>January 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2017</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were a total of 69 consents in the study, 31 of which were randomized (started study medication). 24 subjects completed the study.
The baseline characteristics reported were for the 24 subjects who completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olanzapine</title>
          <description>5mg BID olanzapine for up to 4 weeks
olanzapine: 5mg BID up to 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Iloperidone</title>
          <description>6mg BID iloperidone up to 4 weeks
iloperidone: 6 mg BID up to 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>BID placebo up to 4 weeks
Placebo: BID up to 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olanzapine</title>
          <description>5mg BID olanzapine for up to 4 weeks
olanzapine: 5mg BID up to 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Iloperidone</title>
          <description>6mg BID iloperidone up to 4 weeks
iloperidone: 6 mg BID up to 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>BID placebo up to 4 weeks
Placebo: BID up to 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Starting BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.7" spread="0.3"/>
                    <measurement group_id="B2" value="23.6" spread="0.6"/>
                    <measurement group_id="B3" value="22.7" spread="0.5"/>
                    <measurement group_id="B4" value="23.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education (years)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.4" lower_limit="14" upper_limit="18"/>
                    <measurement group_id="B2" value="13.6" lower_limit="12" upper_limit="16"/>
                    <measurement group_id="B3" value="14.9" lower_limit="13" upper_limit="16"/>
                    <measurement group_id="B4" value="15" lower_limit="12" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Weight</title>
        <description>Delineate a pathophysiological mechanism of antipsychotic induced weight gain</description>
        <time_frame>baseline and 6 week visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>5mg BID olanzapine for up to 4 weeks
olanzapine: 5mg BID up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Iloperidone</title>
            <description>6mg BID iloperidone up to 4 weeks
iloperidone: 6 mg BID up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>BID placebo up to 4 weeks
Placebo: BID up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>Delineate a pathophysiological mechanism of antipsychotic induced weight gain</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.0"/>
                    <measurement group_id="O2" value="0.8" spread="0.7"/>
                    <measurement group_id="O3" value="0.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Adiposity</title>
        <description>Total fat mass (excluding head) from baseline to Day 28</description>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>5mg BID olanzapine for up to 4 weeks
olanzapine: 5mg BID up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Iloperidone</title>
            <description>6mg BID iloperidone up to 4 weeks
iloperidone: 6 mg BID up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>BID placebo up to 4 weeks
Placebo: BID up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Adiposity</title>
          <description>Total fat mass (excluding head) from baseline to Day 28</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11942" spread="3635"/>
                    <measurement group_id="O2" value="14741" spread="7349"/>
                    <measurement group_id="O3" value="11690" spread="5469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13312" spread="4246"/>
                    <measurement group_id="O2" value="16366" spread="6857"/>
                    <measurement group_id="O3" value="12081" spread="4649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Leptin</title>
        <description>Leptin levels measured at Day 3 compared to baseline</description>
        <time_frame>change in baseline to Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>5mg BID olanzapine for up to 4 weeks
olanzapine: 5mg BID up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Iloperidone</title>
            <description>6mg BID iloperidone up to 4 weeks
iloperidone: 6 mg BID up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>BID placebo up to 4 weeks
Placebo: BID up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Leptin</title>
          <description>Leptin levels measured at Day 3 compared to baseline</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="1.17"/>
                    <measurement group_id="O2" value="1.76" spread="0.8"/>
                    <measurement group_id="O3" value="1.16" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change Glucose in People Taking Olanzapine or Iloperidone</title>
        <description>To quantify, prospectively, change in glucose from baseline to Day 28</description>
        <time_frame>Baseline to study termination (about 12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>5mg BID olanzapine for up to 4 weeks
olanzapine: 5mg BID up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Iloperidone</title>
            <description>6mg BID iloperidone up to 4 weeks
iloperidone: 6 mg BID up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>BID placebo up to 4 weeks
Placebo: BID up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change Glucose in People Taking Olanzapine or Iloperidone</title>
          <description>To quantify, prospectively, change in glucose from baseline to Day 28</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11500.71" spread="2721.448"/>
                    <measurement group_id="O2" value="14430" spread="2148.776"/>
                    <measurement group_id="O3" value="10925.5" spread="1134.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11276.43" spread="1231.773"/>
                    <measurement group_id="O2" value="13975" spread="3813.754"/>
                    <measurement group_id="O3" value="12179.5" spread="1252.944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Insulin</title>
        <description>Change in Insulin levels from baseline to Day 28</description>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>5mg BID olanzapine for up to 4 weeks
olanzapine: 5mg BID up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Iloperidone</title>
            <description>6mg BID iloperidone up to 4 weeks
iloperidone: 6 mg BID up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>BID placebo up to 4 weeks
Placebo: BID up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin</title>
          <description>Change in Insulin levels from baseline to Day 28</description>
          <units>mlU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7749" spread="3.42727"/>
                    <measurement group_id="O2" value="9.9316" spread="2.29266"/>
                    <measurement group_id="O3" value="10.9619" spread="2.66812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0862" spread="7.39234"/>
                    <measurement group_id="O2" value="10.873" spread="5.9051"/>
                    <measurement group_id="O3" value="10.785" spread="2.62637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Insulin Resistance</title>
        <description>Homeostatic model assessment for Insulin Resistance (HOMA-IR) is a method for assessing Î²-cell function and insulin resistance (IR) from basal (fasting) glucose and insulin.</description>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>5mg BID olanzapine for up to 4 weeks
olanzapine: 5mg BID up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Iloperidone</title>
            <description>6mg BID iloperidone up to 4 weeks
iloperidone: 6 mg BID up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>BID placebo up to 4 weeks
Placebo: BID up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Resistance</title>
          <description>Homeostatic model assessment for Insulin Resistance (HOMA-IR) is a method for assessing Î²-cell function and insulin resistance (IR) from basal (fasting) glucose and insulin.</description>
          <units>HOMA-IR score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0477" spread="0.70188"/>
                    <measurement group_id="O2" value="2.0661" spread="0.56517"/>
                    <measurement group_id="O3" value="2.2988" spread="0.52346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6147" spread="1.78901"/>
                    <measurement group_id="O2" value="2.4733" spread="1.60855"/>
                    <measurement group_id="O3" value="2.3362" spread="0.68093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Food Intake</title>
        <description>Total grams of food consumed</description>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>5mg BID olanzapine for up to 4 weeks
olanzapine: 5mg BID up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Iloperidone</title>
            <description>6mg BID iloperidone up to 4 weeks
iloperidone: 6 mg BID up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>BID placebo up to 4 weeks
Placebo: BID up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Food Intake</title>
          <description>Total grams of food consumed</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1101.7715" spread="288.60787"/>
                    <measurement group_id="O2" value="1196.6557" spread="527.22574"/>
                    <measurement group_id="O3" value="1567.526" spread="608.53519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1198.4071" spread="303.15123"/>
                    <measurement group_id="O2" value="1154.1286" spread="686.19597"/>
                    <measurement group_id="O3" value="1458.108" spread="731.06392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Lipid Metabolism</title>
        <description>Change in lipid metabolism as measured by cholesterol/HDL ratio</description>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>5mg BID olanzapine for up to 4 weeks
olanzapine: 5mg BID up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Iloperidone</title>
            <description>6mg BID iloperidone up to 4 weeks
iloperidone: 6 mg BID up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>BID placebo up to 4 weeks
Placebo: BID up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lipid Metabolism</title>
          <description>Change in lipid metabolism as measured by cholesterol/HDL ratio</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="0.756"/>
                    <measurement group_id="O2" value="2.57" spread="0.787"/>
                    <measurement group_id="O3" value="2.7" spread="0.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" spread="1.069"/>
                    <measurement group_id="O2" value="2.57" spread="0.787"/>
                    <measurement group_id="O3" value="2.5" spread="0.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Olanzapine</title>
          <description>5mg BID olanzapine for up to 4 weeks
olanzapine: 5mg BID up to 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Iloperidone</title>
          <description>6mg BID iloperidone up to 4 weeks
iloperidone: 6 mg BID up to 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>BID placebo up to 4 weeks
Placebo: BID up to 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Fatigue</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey A. Lieberman, MD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646-774-8436</phone>
      <email>jlieberman@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

